Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: ABX-CBL; Anti-CD147 monoclonal antibody ABX-CBL; CBL-1; Monoclonal antibody ABX-CBL; Monoclonal antibody CBL-1

Latest Information Update: 05 Apr 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abgenix; CV Cancer Center
  • Developer Abgenix; SangStat
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease

Highest Development Phases

  • Discontinued Graft-versus-host disease; Psoriasis; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 21 Feb 2003 Data from a media release with results of a trial comparing gavilimomab with Atgam® for the treatment of steroid-resistant GVHD have been added to the Transplant Rejection therapeutic trials field
  • 18 Feb 2003 Discontinued - Preclinical for Psoriasis in USA (unspecified route)
  • 18 Feb 2003 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top